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INTRODUCTION
Acute myeloid leukemia (AML) comprises a heterogeneous
group of hematological malignancies that arise within the
bone marrow precursors of the myeloid, monocyte, erythroid,
and megakaryocytic cell lineages. AML makes up 15% to
25% of childhood leukemia and accounts for more than 30%
of the deaths from leukemia. The predictors of favorable prog-
nosis in AML include favorable cytogenetics such as t(15;17),
inv(16) and t(8;21) (1-3), and a good response to induction
chemotherapy (3-6).
Recently, the accumulation of knowledge on the molecu-
lar biology of malignancies has led to new diagnostic modal-
ities to be incorporated into various diagnostic and therapeu-
tic strategies (7, 8). One of these modalities is the quantita-
tive reverse transcriptase-polymerase chain reaction (RT-PCR),
which allows researchers to examine the expression patterns
of a large number of genes at the RNA level. It would be
possible to refine the current prognosis-based stratification
systems if specific patterns of gene expression can be correlat-
ed with the prognosis in childhood AML.
Apoptosis is an active biological mechanism leading to pro-
grammed cell death. The up-regulation of antiapoptotic reg-
ulators would certainly be advantageous for tumor survival
(9). Over the last decade, a complex network of pro- and anti-
apoptotic proteins, which strictly regulate the apoptosis path-
ways, has been revealed. In particular, a group of proteins
known as the inhibitor of apoptosis proteins (IAPs) were iden-
tified (10, 11). The IAPs are a family of proteins that have
one to three baculovirus IAP repeat (BIR) domains, and inhib-
it apoptosis by direct binding and inhibiting caspases. Stud-
ies investigating the expression of these molecules in acute
leukemia have demonstrated that the expression of pro- or
antiapoptotic regulators varies depending on the types of leu-
kemias and individual patients’ characteristics (12-23). These
differences can be potentially important for the prediction
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Overexpression of X-linked Inhibitor of Apoptosis Protein (XIAP) is an
Independent Unfavorable Prognostic Factor in Childhood de Novo
Acute Myeloid Leukemia
The overexpression of X-linked inhibitor of apoptosis protein (XIAP), a member of
IAP family protein, is intuitively expected to be associated with unfavorable clinical
features in malignancies; however, there have been only a very limited number of
studies reporting the clinical relevance of XIAP expression. This study was performed
to investigate the prognostic relevance of XIAP expression in childhood acute myeloid
leukemia (AML). In 53 children with de novo AML, the level of XIAP expression was
determined by using quantitative reverse transcriptase-polymerase chain reaction
and was analyzed with respect to the clinical characteristics at diagnosis and treat-
ment outcomes. As a result, the XIAP expression was found to be higher in patients
with extramedullary disease than in those without (P=0.014). In addition, XIAP over-
expression (≥median expression) was associated with an unfavorable day 7 res-
ponse to induction chemotherapy and also associated with a worse 3-yr relapse-
free survival rate (52.7±20.9% vs. 85.9±14.8%, P=0.014). Multivariate analyses
revealed that XIAP overexpression was an independent unfavorable prognostic
factor for relapse-free survival (hazard ratio, 6.16; 95% confidence interval, 1.48-
25.74; P=0.013). Collectively, XIAP overexpression may be used as an unfavorable
prognostic marker in childhood AML.
Key Words : X-Linked Inhibitor of Apoptosis Protein; Apoptosis; Inhibitor of Apoptosis Protein; Leukemia,
Myeloid, Acute
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X-linked inhibitor of apoptosis protein (XIAP, MIM#
300079; baculoviral IAP repeat-containing 4, BIRC4; also
known as hILP and MIHA) gene is located on the chromo-
some band Xq25 and encodes a cytoplasmic protein of 497
amino acids, 57 kDa (24). XIAP contains 3 tandem BIR
domains and a really interesting new gene (RING) domain.
It binds and inhibits caspases 3, 7, and 9, but it does not bind
or inhibit caspase 8. Through its ability to inhibit apopto-
sis, XIAP is intuitively expected to be associated with unfa-
vorable clinical features in malignant diseases; however, only
a very limited number of clinical studies on the prognostic
relevance of XIAP expression in AML, in particular, child-
hood AML are available to date (14, 15).
In this study, therefore, the authors analyzed the expres-
sion of XIAP in 53 children with de novo AML using quan-
titative RT-PCR to determine the possible relationship be-
tween the XIAP expression and the clinical features at diag-
nosis and treatment outcomes. As a result, XIAP overexpres-
sion was found to be strongly associated with both unfavor-
able early responses to induction chemotherapy and worse
long-term treatment outcomes. This is the first study demon-
strating that XIAP overexpression is an independent unfa-
vorable prognostic factor for relapse-free survival (RFS) in
childhood AML.
MATERIALS AND METHODS
Patients and treatment protocol
Children younger than 15 yr of age who were newly diag-
nosed with de novo AML from July 2000 to April 2006 were
enrolled in this study. The diagnosis of AML was made based
on a morphologic assessment of the Wright-Giemsa-stained
smears of the bone marrow aspirates along with special stains
and immunophenotyping by flow cytometry. Laboratory in-
vestigation included conventional and molecular cytogenet-
ic analyses.
All patients were treated according to the modified Kore-
an Biologic Response Modifier Society (KBRMS) protocol
(Table 1). The patients with AML other than acute promye-
locytic leukemia (APL) first received 10 days of induction
chemotherapy, in which the dose of behenoyl cytosine arabi-
noside (BH-AC) for the last 3 days was modified according
to the bone marrow response on day 7. Discontinuation of
the chemotherapy was allowed before the completion of the
induction regimen in patients who experienced sepsis syn-
drome if at least 7 days of induction chemotherapy had been
provided. If complete remission (CR) was not achieved after
the primary induction chemotherapy regimen, an addition-
al course of induction chemotherapy using high-dose cyto-
sine arabinoside was administered. Once CR had been achi-
eved, patients with an appropriate stem cell donor received
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KBRMS, Korean Biologic Response Modifier Society; BH-AC, behenoyl cytosine arabinoside; BM, bone marrow; IV, intravenous injection; IT, intrathe-
cal injection; PO, oral ingestion.
Regimen Drug Dose Schedule
Primary induction BH-AC 300 mg/m
2/day IV, days 0-6
300 mg/m
2/day IV, days 7-9 (if less than 5% BM blasts on day 7)
400 mg/m
2/day IV. days 7-9 (if 6%-25% BM blasts on day 7)
500 mg/m
2/day IV, days 7-9 (if at least 25% BM blasts on day 7)
Idarubicin 12 mg/m
2/day IV, days 0-2
6-thioguanine 100 mg/m
2/day PO, days 0-6
Cytarabine 20 mg/m
2/day  IT, day 0 (if age younger than 1 yr)
30 mg/m
2/day IT, day 0 (if age between 1 and 2 yr)
50 mg/m
2/day IT, day 0 (if age between 2 and 3 yr)
70 mg/m
2/day IT, day 0 (if age at least 3 yr)
Secondary induction Cytarabine 6,000 mg/m
2/day IV, days 0-3
1st consolidation BH-AC 200 mg/m
2/day IV, days 0-4
Idarubicin 12 mg/m
2/day IV, days 0 & 1
Cytarabine 20-70 mg/m
2/day IT, day 0 (different doses according to age)
2nd consolidation BH-AC 200 mg/m
2/day IV, days 0-4
Mitoxantrone 12 mg/m
2/day IV, days 0 & 1
Cytarabine 20-70 mg/m
2/day  IT, day 0 (different doses according to age)
3rd consolidation Etoposide 100 mg/m
2/day IV, days 0-4
Amsacrine 100 mg/m
2/day IV, days 0 & 1
Cytarabine 20-70 mg/m
2/day  IT, day 0 (different doses according to age)
4th consolidation Etoposide 100 mg/m
2/day IV, days 0-4
Mitoxantrone 12 mg/m
2/day IV, days 0 & 1
Cytarabine 20-70 mg/m
2/day  IT, day 0 (different doses according to age)
Table 1. The modified KBRMS protocolconsolidation chemotherapy until the hematopoietic stem
cell transplantation. An entire course of consolidation che-
motherapy was administered in patients without an appro-
priate stem cell donor and in patients with Down syndrome.
For patients with APL, the induction regimen was com-
posed of all-trans-retinoic acid (ATRA, 45 mg/m2/day from
day 0 until CR was achieved) and idarubicin (12 mg/m2/day
on days 1, 3, 5, and 7). Once CR had been achieved, the pa-
tients received 3 courses of consolidation chemotherapy (1st,
2nd, and 4th consolidation chemotherapy according to the
modified KBRMS protocol) along with daily ATRA (45 mg/
m2/day). The patients then received the maintenance chem-
otherapy (ATRA 45 mg/m2/day for 15 days every 12 weeks,
6-mercaptopurine 50 mg/m2/day daily and methotrexate 10
mg/m2/day weekly) over a 2-yr period.
The Institutional Review Board of Samsung Medical Cen-
ter approved this study, and informed consent was obtained
from parents or guardians for both the laboratory studies and
treatment.
RNA isolation and real-time quantitative RT-PCR
Mononuclear cells (MNCs) were isolated from 2 mL of
bone marrow aspirate at diagnosis by ficoll density gradient
centrifugation. The total RNA was extracted from the MNCs
using a QIAamp RNA Blood kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. After treatment
with DNA-free (Ambion, Austin, TX, U.S.A.) to remove
the chromosomal DNA, the complementary DNA (cDNA)
was synthesized using oligo (dT) 15-mer primer by Super-
Script III Reverse Transcriptase (Invitrogen, Carlsbad, CA,
U.S.A.) and stored at -20℃ until use. The mRNA expression
levels of XIAP and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) were measured by quantitative RT-PCR using
ABI PRISM 7000 Sequence Detector System (Applied Bios-
ystems, Foster City, CA, U.S.A.). The quantitative RT-PCR
amplification was performed using the predeveloped Assay-
on-Demand Gene Expression Set for the XIAP gene (Hs015-
97783_m1; GenBank accession no. NM_ 001167.2; Applied
Biosystems) and TaqMan GAPDH Control Reagents (Appli-
ed Biosystems) for the GAPDH gene in combination with
the TaqMan Universal PCR Master Mix (Applied Biosystems).
All reactions were performed in triplicate using 20 μ L sam-
ples containing 50 ng cDNA. The reaction protocol used in-
volved heating for 2 min at 50℃ and 10 min at 95℃, fol-
lowed by 40 cycles of amplification (15 sec at 95℃and 1 min
at 60℃). Analysis was performed using ABI PRISM 7000
Sequence Detection software (Applied Biosystems). The lev-
els of XIAP expression in unknown samples were calculated
as a ratio of XIAP to GAPDH. The levels of XIAP and GA-
PDH mRNA expression were quantified using the standard
curves generated from known serial dilutions of the standard
RNA obtained from A549 cells by assuming a linear relation-
ship between the first cycle number, at which the fluorescence
signal significantly increased (Ct value), and the logarithm
of the starting quantity. A negative control without a tem-
plate was included in each experiment.
Cytotoxicity assay
Cytotoxicity assay was done to evaluate the ex vivo suscep-
tibility of leukemic blasts to apoptotic stimuli provided by
chemotherapeutic agents. Survival of leukemic blasts after
the exposure to etoposide was assessed by measuring the con-
version of the trazolium salt WST-8 to formazan according
to the manufacturer’s instructions (Cell Counting Kit-8; Do-
jindo, Kumamoto, Japan) (12, 25). Briefly, leukemic cells
(1.5×105 cells/well) in RPMI-1640 media supplemented
with 10% fetal bovine serum and penicillin were plated onto
96-well plates. The cells were cultured in triplicate wells with
1 mM etoposide for 24, 48 and 72 hr in a humidified atmo-
sphere containing 5% CO2 at 37℃. At the end of each time
point, 10 μ L WST-8 was added to each well, and the plates
were incubated for additional 4 hr at 37℃ to convert WST-
8 into formazan. The absorbance of each plate was measured
at 450 nm and 600 nm. The absorbance at 450 nm repre-
sents a direct correlation with the cell number in this analy-
sis. The results were expressed as the percentage of the abso-
rbance of control (untreated and serial diluted) cells. The con-
trol cell number was assessed by trypan blue exclusion (final
concentration, 0.2%) for 5 min using a hemocytometer.
Statistical analysis
Differences in the XIAP expression level with respect to
the clinical factors at diagnosis (i.e., sex, age, leukocyte count,
the presence or absence of extramedullary disease, French-
American-British [FAB] classification [26], structural cyto-
genetic abnormalities and FLT3 gene mutations) and treat-
ment outcomes (day 7 response to induction chemotherapy,
induction of remission with the primary induction chemot-
herapy regimen and occurrence of relapse) were analyzed using
the Mann-Whitney U test. The expression levels are present-
ed as the median values along with the ranges. The patients
were categorized into 2 groups according to the level of XIAP
expression (≥median vs. <median). The proportion of pat-
ients with an unfavorable day 7 response and patients in
whom leukemia relapsed in the 2 groups of patients was com-
pared using the Pearson chi-square test. Event-free survival
(EFS) and relapse-free survival (RFS) rates along with 95%
confidence interval (CI) were estimated using the Kaplan-
Meier method. An event was defined as the occurrence of
leukemia relapse or treatment-related death. The differences
in the survival rates between 2 groups according to the XIAP
expression levels (≥median vs. <median) were compared
using the log-rank test. Multivariate analyses comprising
clinical factors for RFS was performed using the Cox regres-
sion analysis. Statistical significance was accepted when the
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RESULTS
Patient characteristics
Fifty-three children were enrolled in this study. Clinical
characteristics of the patients are presented in Table 2. The
median age at diagnosis among the 53 patients (32 boys and
21 girls) was 81 (range 2-179) months, and their median
leukocyte count at diagnosis was 20,460/μ L (range 440-
345,950/μ L). When the disease was classified according to
the FAB classification, 1 patient had AML M0, 28 had M1/
M2, 5 had M3, 13 had M4/M5 and 6 had M7. Three patients
had Down syndrome, and one of them had FAB M7 subtype.
The common structural abnormalities identified by conven-
tional chromosomal analysis, fluorescence in situ hybridiza-
tion examination, or both were t(8;21) in 11 patients, t(15;
17) in 5 patients, 11q23 rearrangement in 11 patients and
inv (16) in 2 patients. Among 12 patients with extramedu-
llary disease, 11 patients had chloroma (scalp in 5 patients,
orbit in 3 patients and skin in 3 patients), and 1 patient had
a central nervous system involvement of leukemic cells. The
FLT3 gene mutation was found in 8 patients among 50 pa-
tients tested, which revealed 4 patients had internal tandem
duplications (ITD) and 4 patients had point mutations in the
tyrosine kinase domain (TKD). Forty-one (77.4%) patients
achieved CR after primary induction chemotherapy. Twen-
ty-nine patients received allogeneic stem cell transplant from
6 related and 23 unrelated donors (14 bone marrow, 11 cord
blood and 4 peripheral blood stem cells) at first CR. The me-
dian proportion of bone marrow leukemic blasts at diagno-
sis was 73 (range 25-98)%. The proportion of patients with
≥50% of bone marrow leukemic blasts at diagnosis was
71.7%. There was no difference in the proportion of bone
marrow leukemic blasts between the patients with XIAP
overexpression (≥median) and those without (P=0.722).
XIAP expression; association with the clinical features at
diagnosis
XIAP expressions with respect to the clinical features at
diagnosis are presented in Table 2. The median expression
level of XIAP in 53 patients was 1.40 (range 0.00-2,867.19).
In 4 patients, XIAP expression was not detected. The level
of XIAP expression was higher in patients with extramedu-
llary disease than in those without (P=0.014; Fig. 1A). The
level of XIAP expression was higher in patients with a high
leukocyte count (≥20,000/μ L) and patients with FLT3-ITD/
TKD mutation than in those without, but the difference was
not significant (Fig. 1B, C). The level of XIAP expression in
3 patients with Down syndrome was not significantly dif-
ferent from that in the remaining patients. There was no dif-
ference in the level of XIAP expression between FAB M2/M3
and M4/M5 subtype or between favorable and intermediate/
unfavorable cytogenetic abnormalities (3). The levels of XIAP
expression in patients with t(15;17), t(8;21) or inv (16) were
not different from those in patients with other cytogenetic
abnormalities (Fig. 1D).
XIAP overexpression; association with a worse early
response to induction chemotherapy
The levels of XIAP expression with respect to responses
to chemotherapy are also presented in Table 2. XIAP over-
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Clinical characteristics No.
XIAP expression
P value
(median)
Sex
Female 21 0.90 0.662
Male 32 1.77
Age
<5 yr 20 2.77 0.263
≥5 yr 33 1.05
Leukocyte count
<20,000/μ L 26 0.89 0.119
≥20,000/μ L 27 3.81
Extramedullary disease
Absent 41 0.90 0.014
Present 12 5.75
FAB classification
M1-M6 47 1.40 0.388
M7 6 3.16
Cytogenetics
Favorable 18 1.77 0.700
Intermediate/unfavorable 35 1.11
FLT3-ITD/TKD mutation
Absent 42 1.39 0.185
Present 8 5.26
Not examined 3 0.24
Day 7 response to treatment
Favorable 30 0.89 0.006
Unfavorable 12 5.82
Undetermined* 11 1.11
Induction of remission
Yes 41 0.90 0.358
No 8 3.95
Not evaluable
� 4 2.46
Relapse
Yes 14 4.87 0.015
No 32 0.86
Toxic death 7 1.74
Differences in the level of XIAP expression were analyzed using the
Mann-Whitney U test. Statistical significance was accepted when the
P values were less than 0.05.
*Day 7 bone marrow examination was not performed in 11 patients (5
patients with APL, 3 patients with severe infection and 3 patients who
experienced early death); 
� Four patients died from toxicity during induc-
tion chemotherapy.
Table 2. The levels of XIAP expression and the treatment out-
comes with respect to the clinical factors of patientsexpression (≥median) was associated with a worse early res-
ponse to induction chemotherapy. The level of XIAP expres-
sion was higher in patients with an unfavorable day 7 response
(defined as leukemic blasts >5% on the bone marrow aspi-
rate on day 7, the presence of a leukemic cell cluster(s) on
the bone marrow biopsy section on day 7 or persistence of
circulating leukemic blasts in the peripheral blood on day
7) than in those with a favorable day 7 response (absence of
any of the three aforementioned findings indicating an unfa-
vorable response) (P=0.006; Fig. 2A). Similarly, the propor-
tion of patients with an unfavorable day 7 response was high-
er in patients with XIAP overexpression (≥median) than
in those without (40.9% vs. 15.0%, P=0.063; Fig. 2B). In
the cytotoxicity assay, the percentage of surviving leukemic
blasts after 24 hr culture with etoposide was higher in patients
with high XIAP expression (upper one-third) than in patients
with low XIAP expression (lower one-third) (P=0.054; Fig.
2C). The level of XIAP expression was also higher in the
patients who did not achieve CR after primary induction
chemotherapy than in those who did; however, the difference
was not significant. Similarly, the induction failure rate with
primary induction chemotherapy regimen due to poor res-
ponse was higher in patients with XIAP overexpression (6
out of 27) than in those without (2 out of 26), albeit with-
out a statistical significance (P=0.138).
XIAP overexpression; association with a worse long-term
RFS rate
The leukemia relapsed in 14 patients, and treatment-relat-
ed mortality occurred in 7 patients. The median follow-up
duration among 32 live patients was 42 (range 20-88) mo-
nths. The 3-yr RFS and EFS rates (±95% CI) in all 53 pa-
tients were 69.0±13.6% and 58.9±13.6%, respectively.
The 3-yr RFS rate in 33 patients (other than AML, M3 or
Down syndrome) who were assigned to receive allogeneic
transplantation at first CR was slightly higher than in 6 pati-
ents who were assigned to receive continuous chemotherapy
alone or autologous transplantation at first CR, but it was not
significant (69.7±15.7% vs. 60.0±42.9%, P=0.981).
The level of XIAP expression was higher in the patients who
experienced relapse than in those who had been in continu-
ous CR (P=0.015; Fig. 3A). Leukemia relapse was more fre-
quent in patients with XIAP overexpression (11 out of 27)
than in those without (3 out of 26) (P=0.016; Fig. 3B). The
3-yr RFS rate was lower in patients with XIAP overexpres-
sion than in those without (52.7±20.9% vs. 85.9±14.8%,
P=0.014; Fig. 3C). Similarly, the 3-yr RFS rate after allogene-
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Fig. 1. The level of XIAP expression with respect to the clinical characteristics at diagnosis. The level of XIAP expression was higher in pa-
tients with extramedullary disease than in those without (A). The level of XIAP expression was higher in patients with high leukocyte counts
(≥20,000/μ L) (B) and patients with FLT3-ITD/TKD mutation than in those without (C), but the differences were not statistically significant.
The expression was not differed by cytogenetic abnormalities (D).
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P=0.119ic transplantation was lower in patients with XIAP overex-
pression than in those without, although it was not signifi-
cant (74.6±16.2% vs. 87.5±25.1%, P=0.339; Fig. 3D).
Multivariate analyses for RFS revealed that XIAP overexpres-
sion was an independent unfavorable prognostic factor with
a statistical significance in childhood AML (hazard ratio, 6.16;
95% CI, 1.48-25.74; P=0.013; Table 3).
DISCUSSION
A variety of anti-apoptotic proteins are expressed in differ-
ent tumors, and their expression levels may be related to the
unfavorable features at diagnosis, a poor response to treatment
or both. However, the clinical relevance of these biological
regulators remains largely elusive, and particularly, there have
been no studies on the prognostic relevance of XIAP expres-
sion in childhood AML to date, except for the only study by
Tamm et al. (15) who demonstrated that a high level of XIAP
expression correlated with a poorer overall survival in child-
hood AML. From this context, the present study was per-
formed to investigate the possible relationship between XIAP
expression and the clinical features in childhood de novo AML.
In the present study, the level of XIAP expression was found
to be associated with the clinical characteristics at diagnosis.
The level of XIAP expression was higher in patients with
extramedullary disease than in those without. In addition,
the level of XIAP expression was higher in patients with a
high leukocyte count and patients with FLT3-ITD/TKD mu-
tation than in those without, although the differences were
not statistically significant. However, there was no signifi-
cant difference in the level of XIAP expression according to
cytogenetic abnormalities (favorable vs. intermediate/ unfa-
vorable), which are known to be the most significant prog-
nostic factor in AML (3). These findings suggest that XIAP
expression is independent of cytogenetic abnormalities in
childhood AML.
The early response to induction chemotherapy has proven
to play an important role in children with acute lymphoblas-
tic leukemia (ALL) (27-29). In childhood ALL, the failure of
achieving blast clearance from the bone marrow aspirates after
1 or 2 weeks of induction chemotherapy (27, 28) or the per-
sistence of circulating blasts after 1 week of multi-agent che-
motherapy (29) indicates a poor prognosis. It is likely that
the initial response to induction chemotherapy may also be
predictive of the outcome in childhood AML, although there
are currently limited data available to draw a definite conclu-
sion. Some studies evaluated the response to induction che-
motherapy by assessing the degree of residual leukemic infi-
ltration in the bone marrow after 6 or 14 days of induction
chemotherapy (4-6). In the present study, the early response
to induction chemotherapy was evaluated on day 7, and the
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Fig. 2. XIAP overexpression: association with a worse early res-
ponse to induction chemotherapy. The level of XIAP expres-
sion was higher in patients with an unfavorable day 7 response
(defined as leukemic blasts > 5% on the bone marrow aspirate
on day 7, the presence of a leukemic cell cluster[s] on the bone
marrow biopsy section on day 7 or persistence of circulating
leukemic blasts in the peripheral blood on day 7) than in those
with a favorable day 7 response (absence of any of the above
findings indicating an unfavorable response) (A). The propor-
tion of patients with an unfavorable day 7 response was higher
in patients with high XIAP expression (≥median) than in
patients with low XIAP expression (<median) (B). In the cytotoxici-
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ty assay, the percentage of surviving leukemic blasts after 24 hr culture with etoposide was higher in patients with high XIAP expression
(upper one-third, n=2) than in those with low XIAP expression (lower one-third, n=2) (C).unfavorable day 7 response was strongly associated with a
worse 3-yr RFS (80.9±15.2% vs. 38.1±28.8%, P=0.008).
Here again, it is of note that the level of XIAP expression was
significantly higher in patients with an unfavorable day 7
response than in those without. Similarly, the proportion of
patients with an unfavorable day 7 response was higher in
patients with XIAP overexpression (≥median) than in
those without. These findings were in line with the result of
in vitro cytotoxicity assay. In addition, the frequency of
induction failure after primary induction chemotherapy due
to poor response was higher in patients with XIAP overex-
pression than in those without, albeit without a statistical
significance. These findings suggest that XIAP overexpres-
sion is associated with a worse early response to induction
chemotherapy. The level of XIAP expression was higher in
patients who experienced relapse than in patients who had
been in continuous CR. Similarly, the frequency of relapse
was higher in patients with XIAP overexpression than in
those without. As a result, the 3-yr RFS rate was lower in
patients with XIAP overexpression than in those without.
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Fig. 3. XIAP overexpression: association with a worse long-term relapse-free survival (RFS) rate. The level of XIAP expression was higher
in the patients who experienced relapse than in those who had been in continuous CR (complete remission) (A). The relapse of disease
was more frequent in patients with XIAP overexpression (11 out of 27) than in those without (3 out of 26) (B). Similarly, the 3-yr RFS rate
was lower in patients with XIAP overexpression than in those without (52.7±20.9% vs. 85.9±14.8%) (C).
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Prognostic impact of each variable was estimated using the Cox regression analysis. Statistical significance was accepted when the P values were
less than 0.05.
HR, hazard ratio; CI, confidence interval.
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Male 1.40 2.47-4.18 0.548 0.96 0.27-3.38 0.953
Age <5 yr 3.00 1.04-8.69 0.042 1.30 0.33-5.08 0.709
Leukocyte count ≥20,000/μ L 1.09 0.38-3.12 0.868 1.29 0.30-5.60 0.732
Presence of extramedullary disease 0.89 0.25-3.20 0.859 0.42 0.09-1.98 0.275
FAB M7 subtype 3.19 0.89-11.48 0.076 1.83 0.32-10.44 0.497
Presence of FLT3-ITD/TKD mutation 1.03 0.23-4.63 0.967 0.55 0.08-3.73 0.537
Intermediate/unfavorable cytogenetics 8.44 1.10-64.53 0.040 10.60 1.14-98.52 0.038
XIAP overexpression (≥median) 4.29 1.19-15.43 0.026 6.16 1.48-25.74 0.013
Table 3. Univariate and multivariate analyses with prognostic factors for relapse-free survivalIn the multivariate analyses, XIAP overexpression was an
independent unfavorable prognostic factor for RFS. Collec-
tively, it was suggested that XIAP overexpression is associ-
ated with delayed blast clearance from the bone marrow or
peripheral blood and the resistance of blasts to apoptotic
stimuli provided by the chemotherapeutic agents, eventual-
ly leading to a worse RFS.
The findings in the present study are basically in line with
those by Tamm et al. (15) in that XIAP overexpression is as-
sociated with a worse outcome. However, there are a few im-
portant differences between the two studies. First, there was
no difference in the level of XIAP expression between FAB
M2/M3 and M4/M5 subtype in the present study, while the
level of XIAP expression was higher in M4/M5 subtype than
in M2/M3 subtype according to the report by Tamm et al.
(15). Second, while Tamm et al. (15) could detect XIAP ex-
pression only in patients with intermediate/unfavorable cyto-
genetics, we detected XIAP expression even in patients with
favorable cytogenetics and there was no difference in the level
of XIAP expression between favorable and intermediate/unfa-
vorable cytogenetics. Third, most importantly, the level of
XIAP expression was higher in patients who experienced
relapse than in those in continuous CR in this study, while
Tamm et al. (15) could not find a significant difference in
XIAP expression between the two groups of patients. As a
result, they could not find a difference in RFS according to
the level of XIAP expression although the high level of XIAP
expression was associated with a worse overall survival rate.
These differences between the two studies may be partly ex-
plained by the difference in methods to measure XIAP expres-
sion (quantitative RT-PCR vs. Western blot). In addition,
as Tamm et al. (15) pointed out in their report, selection bias
toward samples from patients with high leukocyte counts
during cryopreservation of samples and alteration in protein
expression by freezing and DMSO might have resulted in
different findings from our study.
The IAP family proteins inhibit the apoptosis induced by
a variety of stimuli including chemotherapeutic agents, and
therefore, their overexpression is expected to be associated
with unfavorable clinical features in a variety of malignan-
cies including AML. However, the clinical significance of
IAP overexpression in acute leukemia is not completely con-
sistent with what has been expected from previous in vitro
studies. For example, IAP overexpression was not always as-
sociated with the unfavorable clinical features in acute leu-
kemia (16). Furthermore, it was recently reported that the
high expression of Livin, also a member of IAP family pro-
teins, is an independent favorable prognostic factor in child-
hood ALL (12). This suggests that the role of IAP in leuke-
mogenesis or in the maintenance of leukemic cells might be
different from what has been previously recognized. How-
ever, the findings from this study demonstrated that the clin-
ical significance of XIAP overexpression in childhood AML
is consistent with what has been previously recognized from
in vitro studies.
In conclusion, this is the first report demonstrating that
XIAP overexpression is associated with a worse early response
to induction chemotherapy and, eventually, is an indepen-
dent unfavorable prognostic factor for RFS in childhood AML.
Admitting that the number of cases and the follow-up period
in this study were limited, we hope this study would prompt
other scientists to investigate the implications of XIAP over-
expression in childhood AML to confirm our observations in
a larger series of patients. Through validation by further stud-
ies, XIAP overexpression may be used as an unfavorable prog-
nostic marker in childhood AML.
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